Sort by
Items per page

Send to

Choose Destination

Best matches for Lethé B[au]:

Search results

Items: 41


A new transcript in the TCRB locus unveils the human ortholog of the mouse pre-Dß1 promoter.

Lethé B, Snauwaert S, Bricard O, Schröder D, Gomard T, Hames G, Muller C, Lurquin C, Gauthy E, Essaghir A, Vandekerckhove B, Coulie PG.

Immun Inflamm Dis. 2017 Sep;5(3):346-354. doi: 10.1002/iid3.172. Epub 2017 May 15.


Local immunostimulation leading to rejection of accepted male skin grafts by female mice as a model for cancer immunotherapy.

Bourdeaux C, Lurquin C, Jacquemart I, Lethé B, Brasseur F, van Baren N, Baurain JF, Dyson J, Van Snick J, Uyttenhove C, Boon T.

Proc Natl Acad Sci U S A. 2014 Mar 4;111(9):3502-7. doi: 10.1073/pnas.1401115111. Epub 2014 Feb 18.


GARP is regulated by miRNAs and controls latent TGF-β1 production by human regulatory T cells.

Gauthy E, Cuende J, Stockis J, Huygens C, Lethé B, Collet JF, Bommer G, Coulie PG, Lucas S.

PLoS One. 2013 Sep 30;8(9):e76186. doi: 10.1371/journal.pone.0076186. eCollection 2013.


Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases.

Corbière V, Chapiro J, Stroobant V, Ma W, Lurquin C, Lethé B, van Baren N, Van den Eynde BJ, Boon T, Coulie PG.

Cancer Res. 2011 Feb 15;71(4):1253-62. doi: 10.1158/0008-5472.CAN-10-2693. Epub 2011 Jan 7.


Vaccination of a melanoma patient with mature dendritic cells pulsed with MAGE-3 peptides triggers the activity of nonvaccine anti-tumor cells.

Carrasco J, Van Pel A, Neyns B, Lethé B, Brasseur F, Renkvist N, van der Bruggen P, van Baren N, Paulus R, Thielemans K, Boon T, Godelaine D.

J Immunol. 2008 Mar 1;180(5):3585-93.


Selective identification of HLA-DP4 binding T cell epitopes encoded by the MAGE-A gene family.

Wang XF, Cohen WM, Castelli FA, Almunia C, Lethé B, Pouvelle-Moratille S, Munier G, Charron D, Ménez A, Zarour HM, van der Bruggen P, Busson M, Maillère B.

Cancer Immunol Immunother. 2007 Jun;56(6):807-18. Epub 2006 Sep 20.


A new LAGE-1 peptide recognized by cytolytic T lymphocytes on HLA-A68 tumors.

Sun Z, Lethé B, Zhang Y, Russo V, Colau D, Stroobant V, Boon T, van der Bruggen P.

Cancer Immunol Immunother. 2006 Jun;55(6):644-52. Epub 2005 Sep 27.


Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma.

Kruit WH, van Ojik HH, Brichard VG, Escudier B, Dorval T, Dréno B, Patel P, van Baren N, Avril MF, Piperno S, Khammari A, Stas M, Ritter G, Lethé B, Godelaine D, Brasseur F, Zhang Y, van der Bruggen P, Boon T, Eggermont AM, Marchand M.

Int J Cancer. 2005 Nov 20;117(4):596-604.


Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen.

Lurquin C, Lethé B, De Plaen E, Corbière V, Théate I, van Baren N, Coulie PG, Boon T.

J Exp Med. 2005 Jan 17;201(2):249-57.


High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens.

Germeau C, Ma W, Schiavetti F, Lurquin C, Henry E, Vigneron N, Brasseur F, Lethé B, De Plaen E, Velu T, Boon T, Coulie PG.

J Exp Med. 2005 Jan 17;201(2):241-8.


Monoclonal anti-MAGE-3 CTL responses in melanoma patients displaying tumor regression after vaccination with a recombinant canarypox virus.

Karanikas V, Lurquin C, Colau D, van Baren N, De Smet C, Lethé B, Connerotte T, Corbière V, Demoitié MA, Liénard D, Dréno B, Velu T, Boon T, Coulie PG.

J Immunol. 2003 Nov 1;171(9):4898-904.


A MAGE-1 peptide recognized on HLA-DR15 by CD4(+) T cells.

Chaux P, Lethé B, Van Snick J, Corthals J, Schultz ES, Cambiaso CL, Boon T, van der Bruggen P.

Eur J Immunol. 2001 Jun;31(6):1910-6.


A MAGE-A3 peptide presented by HLA-DP4 is recognized on tumor cells by CD4+ cytolytic T lymphocytes.

Schultz ES, Lethé B, Cambiaso CL, Van Snick J, Chaux P, Corthals J, Heirman C, Thielemans K, Boon T, van der Bruggen P.

Cancer Res. 2000 Nov 15;60(22):6272-5.


DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter.

De Smet C, Lurquin C, Lethé B, Martelange V, Boon T.

Mol Cell Biol. 1999 Nov;19(11):7327-35.


Quantitative evaluation of the expression of MAGE genes in tumors by limiting dilution of cDNA libraries.

Serrano A, Lethé B, Delroisse JM, Lurquin C, De Plaen E, Brasseur F, Rimoldi D, Boon T.

Int J Cancer. 1999 Nov 26;83(5):664-9.


Reliability of reverse transcription-polymerase chain reaction (RT-PCR)-based assays for the detection of circulating tumour cells: a quality-assurance initiative of the EORTC Melanoma Cooperative Group.

Keilholz U, Willhauck M, Rimoldi D, Brasseur F, Dummer W, Rass K, de Vries T, Blaheta J, Voit C, Lethé B, Burchill S.

Eur J Cancer. 1998 Apr;34(5):750-3.


Cotranscription and intergenic splicing of human galactose-1-phosphate uridylyltransferase and interleukin-11 receptor alpha-chain genes generate a fusion mRNA in normal cells. Implication for the production of multidomain proteins during evolution.

Magrangeas F, Pitiot G, Dubois S, Bragado-Nilsson E, Chérel M, Jobert S, Lebeau B, Boisteau O, Lethé B, Mallet J, Jacques Y, Minvielle S.

J Biol Chem. 1998 Jun 26;273(26):16005-10.


LAGE-1, a new gene with tumor specificity.

Lethé B, Lucas S, Michaux L, De Smet C, Godelaine D, Serrano A, De Plaen E, Boon T.

Int J Cancer. 1998 Jun 10;76(6):903-8.


Identification of a new MAGE gene with tumor-specific expression by representational difference analysis.

Lucas S, De Smet C, Arden KC, Viars CS, Lethé B, Lurquin C, Boon T.

Cancer Res. 1998 Feb 15;58(4):743-52.


MAGE-1 expression threshold for the lysis of melanoma cell lines by a specific cytotoxic T lymphocyte.

Lethé B, van der Bruggen P, Brasseur F, Boon T.

Melanoma Res. 1997 Aug;7 Suppl 2:S83-8.


Identification of genes coding for tumor antigens recognized by cytolytic T lymphocytes.

De Plaen E, Lurquin C, Lethé B, van der Bruggen P, Brichard V, Renauld JC, Coulie P, Van Pel A, Boon T.

Methods. 1997 Jun;12(2):125-42. Review.


Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor.

Ikeda H, Lethé B, Lehmann F, van Baren N, Baurain JF, de Smet C, Chambost H, Vitale M, Moretta A, Boon T, Coulie PG.

Immunity. 1997 Feb;6(2):199-208.


The expression of mouse gene P1A in testis does not prevent safe induction of cytolytic T cells against a P1A-encoded tumor antigen.

Uyttenhove C, Godfraind C, Lethé B, Amar-Costesec A, Renauld JC, Gajewski TF, Duffour MT, Warnier G, Boon T, Van den Eynde BJ.

Int J Cancer. 1997 Jan 27;70(3):349-56.


A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyltransferase V gene.

Guilloux Y, Lucas S, Brichard VG, Van Pel A, Viret C, De Plaen E, Brasseur F, Lethé B, Jotereau F, Boon T.

J Exp Med. 1996 Mar 1;183(3):1173-83.


A tyrosinase nonapeptide presented by HLA-B44 is recognized on a human melanoma by autologous cytolytic T lymphocytes.

Brichard VG, Herman J, Van Pel A, Wildmann C, Gaugler B, Wölfel T, Boon T, Lethé B.

Eur J Immunol. 1996 Jan;26(1):224-30.


Expression of MAGE genes in primary and metastatic cutaneous melanoma.

Brasseur F, Rimoldi D, Liénard D, Lethé B, Carrel S, Arienti F, Suter L, Vanwijck R, Bourlond A, Humblet Y, et al.

Int J Cancer. 1995 Nov 3;63(3):375-80.


A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma.

Coulie PG, Lehmann F, Lethé B, Herman J, Lurquin C, Andrawiss M, Boon T.

Proc Natl Acad Sci U S A. 1995 Aug 15;92(17):7976-80.


Genes coding for tumor antigens recognized by cytolytic T lymphocytes.

Van Pel A, van der Bruggen P, Coulie PG, Brichard VG, Lethé B, van den Eynde B, Uyttenhove C, Renauld JC, Boon T.

Immunol Rev. 1995 Jun;145:229-50. Review. No abstract available.


Expression of mage genes by non-small-cell lung carcinomas.

Weynants P, Lethé B, Brasseur F, Marchand M, Boon T.

Int J Cancer. 1994 Mar 15;56(6):826-9.


Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes.

Gaugler B, Van den Eynde B, van der Bruggen P, Romero P, Gaforio JJ, De Plaen E, Lethé B, Brasseur F, Boon T.

J Exp Med. 1994 Mar 1;179(3):921-30.


Structure, chromosomal localization, and expression of 12 genes of the MAGE family.

De Plaen E, Arden K, Traversari C, Gaforio JJ, Szikora JP, De Smet C, Brasseur F, van der Bruggen P, Lethé B, Lurquin C, et al.

Immunogenetics. 1994;40(5):360-9.


The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas.

Brichard V, Van Pel A, Wölfel T, Wölfel C, De Plaen E, Lethé B, Coulie P, Boon T.

J Exp Med. 1993 Aug 1;178(2):489-95.


Human T cell lines and clones respond to IL-9.

Houssiau FA, Renauld JC, Stevens M, Lehmann F, Lethe B, Coulie PG, Van Snick J.

J Immunol. 1993 Apr 1;150(7):2634-40.


Human gene MAGE-1, which codes for a tumor-rejection antigen, is expressed by some breast tumors.

Brasseur F, Marchand M, Vanwijck R, Hérin M, Lethé B, Chomez P, Boon T.

Int J Cancer. 1992 Nov 11;52(5):839-41. No abstract available.


Mouse tumor rejection antigens P815A and P815B: two epitopes carried by a single peptide.

Lethé B, van den Eynde B, van Pel A, Corradin G, Boon T.

Eur J Immunol. 1992 Sep;22(9):2283-8.


Tum- antigens, TSTA, and T cell immune surveillance.

Van Pel A, Warnier G, Van den Eynde B, Lethé B, Lurquin C, Boon T.

Ann N Y Acad Sci. 1991 Dec 30;636:43-51. Review. No abstract available.


The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice.

Van den Eynde B, Lethé B, Van Pel A, De Plaen E, Boon T.

J Exp Med. 1991 Jun 1;173(6):1373-84.


Genes coding for T-cell-defined tum transplantation antigens: point mutations, antigenic peptides, and subgenic expression.

Boon T, Van Pel A, De Plaen E, Chomez P, Lurquin C, Szikora JP, Sibille C, Mariamé B, Van den Eynde B, Lethé B, et al.

Cold Spring Harb Symp Quant Biol. 1989;54 Pt 1:587-96. Review. No abstract available.


Identification of genes encoding T cell defined tum- antigens.

Van Pel A, De Plaen E, Lurquin C, Van den Eynde B, Lethé B, Hainaut P, Lemoine C, Boon T.

Princess Takamatsu Symp. 1988;19:255-63.


Supplemental Content

Support Center